Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. [L'application topique de médicaments anti-fibrinolytiques pour la chirurgie cardiaque avec circulation extra-corporelle : analyse méthodique et méta-analyse.] [English, French abstract] (отвара нови прозор)

Abrishami A, Chung F, Wong J.

Извор‎: Can J Anaesth 2009;56(3):202-12.

Индекс‎: PubMed 19247741

DOI‎: 10.1007/s12630-008-9038-x

https://www.ncbi.nlm.nih.gov/pubmed/19247741 (отвара нови прозор)

Can topical application of tranexamic acid reduce blood loss in thoracic surgery? A prospective randomised double blind investigation. (отвара нови прозор)

Dell'Amore A, Caroli G, Nizar A, Cassanelli N, Luciano G, Greco D, Dolci G, Bini A, Stella F.

Извор‎: Heart Lung Circ 2012;21(11):706-10.

Индекс‎: PubMed 22842057

DOI‎: 10.1016/j.hlc.2012.06.016

https://www.ncbi.nlm.nih.gov/pubmed/22842057 (отвара нови прозор)

Can local application of tranexamic acid reduce post-coronary bypass surgery blood loss? A randomized controlled trial. (отвара нови прозор)

Fawzy H, Elmistekawy E, Bonneau D, Latter D, Errett L.

Извор‎: J Cardiothorac Surg 2009;4:25.

Индекс‎: PubMed 19538741

DOI‎: 10.1186/1749-8090-4-25

https://www.ncbi.nlm.nih.gov/pubmed/19538741 (отвара нови прозор)

Current status of pharmacologic therapies in patient blood management. (отвара нови прозор)

Goodnough LT, Shander A.

Извор‎: Anesth Analg 2013;116(1):15-34.

Индекс‎: PubMed 23223098

DOI‎: 10.1213/ANE.0b013e318273f4ae

https://www.ncbi.nlm.nih.gov/pubmed/23223098 (отвара нови прозор)

The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial. (отвара нови прозор)

Greilich PE, Jessen ME, Satyanarayana N, Whitten CW, Nuttall GA, Beckham JM, Wall MH, Butterworth JF.

Извор‎: Anesth Analg 2009;109(1):15-24.

Индекс‎: PubMed 19535691

DOI‎: 10.1213/ane.0b013e3181a40b5d

https://www.ncbi.nlm.nih.gov/pubmed/19535691 (отвара нови прозор)

Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. (отвара нови прозор)

Howell N, Senanayake E, Freemantle N, Pagano D.

Извор‎: J Thorac Cardiovasc Surg 2013;145(1):234-40.

Индекс‎: PubMed 22889481

DOI‎: 10.1016/j.jtcvs.2012.07.018

https://www.ncbi.nlm.nih.gov/pubmed/22889481 (отвара нови прозор)

The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. (отвара нови прозор)

Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS.

Извор‎: Anesth Analg 2010;110(1):21-9.

Индекс‎: PubMed 19910626

DOI‎: 10.1213/ANE.0b013e3181c0ea6d

https://www.ncbi.nlm.nih.gov/pubmed/19910626 (отвара нови прозор)

Comparative evaluation of the effects of tranexamic acid and low-dose aprotinin on post-valvular heart surgery bleeding and allogenic transfusion. (отвара нови прозор)

Mansouri M, Attary M, Bagheri K, Massoumi G, Ghavami B.

Извор‎: Interact Cardiovasc Thorac Surg 2012;15(1):23-7.

Индекс‎: PubMed 22514257

DOI‎: 10.1093/icvts/ivs114

https://www.ncbi.nlm.nih.gov/pubmed/22514257 (отвара нови прозор)

A randomized trial of tranexamic acid in combination with cell salvage plus a meta-analysis of randomized trials evaluating tranexamic acid in off-pump coronary artery bypass grafting. (отвара нови прозор)

Murphy GJ, Mango E, Lucchetti V, Battaglia F, Catapano D, Rogers CA, Angelini GD.

Извор‎: J Thorac Cardiovasc Surg 2006;132(3):475-80, 480.e1-8.

Индекс‎: PubMed 16935098

DOI‎: 10.1016/j.jtcvs.2006.01.064

https://www.ncbi.nlm.nih.gov/pubmed/16935098 (отвара нови прозор)

Tranexamic acid in patients undergoing coronary-artery surgery. (отвара нови прозор)

Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussières JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S, ATACAS Investigators of the ANZCA Clinical Trials Network

Извор‎: N Engl J Med 2017;376(2):136-48.

Индекс‎: PubMed 27774838

DOI‎: 10.1056/NEJMoa1606424

http://www.ncbi.nlm.nih.gov/pubmed/27774838 (отвара нови прозор)

Aprotinin for patients exposed to clopidogrel before off-pump coronary bypass. (отвара нови прозор)

Nurözler F, Kutlu T, Küçük G.

Извор‎: Asian Cardiovasc Thorac Ann 2008;16(6):483-7.

Индекс‎: PubMed 18984759

DOI‎: 10.1177/021849230801600611

https://www.ncbi.nlm.nih.gov/pubmed/18984759 (отвара нови прозор)

Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial. (отвара нови прозор)

Shi J, Ji H, Ren F, Wang G, Xu M, Xue Y, Chen M, Qi J, Li L.

Извор‎: JAMA Surg 2013;148(6):538-47.

Индекс‎: PubMed 23426385

DOI‎: 10.1001/jamasurg.2013.1560

https://www.ncbi.nlm.nih.gov/pubmed/23426385 (отвара нови прозор)

Effect of high- vs low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery: The OPTIMAL randomized clinical trial. (отвара нови прозор)

Shi J, Zhou C, Pan W, Sun H, Liu S, Feng W, Wang W, Cheng Z, Wang Y, Zheng Z

Извор‎: JAMA. 2022;328(4):336-47.

Индекс‎: PubMed 35881121

DOI‎:  10.1001/jama.2022.10725

https://pubmed.ncbi.nlm.nih.gov/35881121/ (отвара нови прозор)

Tranexamic acid reduces blood loss after off-pump coronary surgery: a prospective, randomized, double-blind, placebo-controlled study. (отвара нови прозор)

Wang G, Xie G, Jiang T, Wang Y, Wang W, Ji H, Liu M, Chen L, Li L.

Извор‎: Anesth Analg 2012;115(2):239-43.

Индекс‎: PubMed 21737704

DOI‎: 10.1213/ANE.0b013e3182264a11

https://www.ncbi.nlm.nih.gov/pubmed/21737704 (отвара нови прозор)

Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery. (отвара нови прозор)

Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, Hu S.

Извор‎: Ann Thorac Surg 2010;89(5):1489-95.

Индекс‎: PubMed 20417766

DOI‎: 10.1016/j.athoracsur.2010.02.006

https://www.ncbi.nlm.nih.gov/pubmed/20417766 (отвара нови прозор)

Low postoperative dose of aprotinin reduces bleeding and is safe in patients receiving clopidogrel before coronary artery bypass surgery. A prospective randomized study. (отвара нови прозор)

Øvrum E, Tangen G, Tølløfsrud S, Ringdal MA, Øystese R, Istad R.

Извор‎: Interact Cardiovasc Thorac Surg 2010;10(4):545-8.

Индекс‎: PubMed 20067988

DOI‎: 10.1510/icvts.2009.226613

https://www.ncbi.nlm.nih.gov/pubmed/20067988 (отвара нови прозор)

Aortic dissection and hypothermic arrest in a Jehovah's Witness patient: a case for recombinant factor VIIa? (отвара нови прозор)

Ballen J, Raabe M, Muirhead B.

Извор‎: Can J Anaesth 2006;53(4):353-6.

Индекс‎: PubMed 16575032

DOI‎: 10.1007/BF03022498

https://www.ncbi.nlm.nih.gov/pubmed/16575032 (отвара нови прозор)

Use of recombinant activated factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications. (отвара нови прозор)

Bhaskar B, Zeigenfuss M, Choudhary J, Fraser JF.

Извор‎: Transfusion 2013;53(4):798-804.

Индекс‎: PubMed 22845023

DOI‎: 10.1111/j.1537-2995.2012.03801.x

https://www.ncbi.nlm.nih.gov/pubmed/22845023 (отвара нови прозор)

Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. (отвара нови прозор)

Dunkley S, Phillips L, McCall P, Brereton J, Lindeman R, Jankelowitz G, Cameron P.

Извор‎: Ann Thorac Surg 2008;85(3):836-44.

Индекс‎: PubMed 18291152

DOI‎: 10.1016/j.athoracsur.2007.06.076

https://www.ncbi.nlm.nih.gov/pubmed/18291152 (отвара нови прозор)

Repeat cardiac surgery in a Jehovah's Witness patient with thrombocytopenia. (отвара нови прозор)

Elmistekawy E, Lapierre H, Bourke M, Dennie C, Labinaz M, Ruel M.

Извор‎: Can J Cardiol 2011;27(6):869.e7-8.

Индекс‎: PubMed 21983113

DOI‎: 10.1016/j.cjca.2011.07.632

https://www.ncbi.nlm.nih.gov/pubmed/21983113 (отвара нови прозор)

Off-label use of recombinant activated factor VII for cardiac surgical bleeding. (отвара нови прозор)

Flynn BC, Steiner ME, Mazzeffi M

Извор‎: Anesthesiology. 2023 1;139(2):197-210.

Индекс‎: PubMed 37155359

DOI‎: 10.1097/ALN.0000000000004569

https://pubmed.ncbi.nlm.nih.gov/37155359/ (отвара нови прозор)

Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. (отвара нови прозор)

Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, Sellke F, Booth F, Schmidt TA.

Извор‎: Circulation 2009;120(1):21-7.

Индекс‎: PubMed 19546387

DOI‎: 10.1161/CIRCULATIONAHA.108.834275

https://www.ncbi.nlm.nih.gov/pubmed/19546387 (отвара нови прозор)

Intraoperative use of recombinant activated factor VII during complex aortic surgery. (отвара нови прозор)

Goksedef D, Panagopoulos G, Nassiri N, Levine RL, Hountis PG, Plestis KA.

Извор‎: J Thorac Cardiovasc Surg 2012;143(5):1198-204.

Индекс‎: PubMed 22285329

DOI‎: 10.1016/j.jtcvs.2012.01.004

https://www.ncbi.nlm.nih.gov/pubmed/22285329 (отвара нови прозор)

Off-label use of recombinant human factor VIIa. (отвара нови прозор)

Goodnough LT, Levy JH.

Извор‎: Ann Thorac Surg 2014;98(2):393-5.

Индекс‎: PubMed 25087781

DOI‎: 10.1016/j.athoracsur.2014.06.007

https://www.ncbi.nlm.nih.gov/pubmed/25087781 (отвара нови прозор)

Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7). (отвара нови прозор)

Hacquard M, Durand M, Lecompte T, Boini S, Briançon S, Carteaux JP.

Извор‎: Eur J Cardiothorac Surg 2011;40(6):1320-7.

Индекс‎: PubMed 21550261

DOI‎: 10.1016/j.ejcts.2011.03.032

https://www.ncbi.nlm.nih.gov/pubmed/21550261 (отвара нови прозор)

Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. (отвара нови прозор)

Karkouti K, Beattie WS, Arellano R, Aye T, Bussieres JS, Callum JL, Cheng D, Heinrich L, Kent B, Lee TW, MacAdams C, Mazer CD, Muirhead B, Rochon AG, Rubens FD, Sawchuk C, Wang S, Waters T, Wong BI, Yau TM.

Извор‎: Circulation 2008;118(4):331-8.

Индекс‎: PubMed 18606914

DOI‎: 10.1161/CIRCULATIONAHA.108.764308

https://www.ncbi.nlm.nih.gov/pubmed/18606914 (отвара нови прозор)

Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery. (отвара нови прозор)

Končar IB, Davidović LB, Savić N, Sinđelić RB, Ilić N, Dragas M, Markovic M, Kostic D.

Извор‎: J Vasc Surg 2011;53(4):1032-7.

Индекс‎: PubMed 21215579

DOI‎: 10.1016/j.jvs.2010.07.075

https://www.ncbi.nlm.nih.gov/pubmed/21215579 (отвара нови прозор)

Use of activated recombinant factor VII in severe bleeding—evidence for efficacy and safety in trauma, postpartum hemorrhage, cardiac surgery, and gastrointestinal bleeding. (отвара нови прозор)

Lau P, Ong V, Tan WT, Koh PL, Hartman M.

Извор‎: Transfus Med Hemother 2012;39(2):139-50.

Индекс‎: PubMed 22670132

DOI‎: 10.1159/000338034

https://www.ncbi.nlm.nih.gov/pubmed/22670132 (отвара нови прозор)

Recombinant activated factor VII for postoperative hemorrhage following repair of acute type A aortic dissection. (отвара нови прозор)

Lehr EJ, Alford TJ, Wang SH.

Извор‎: Heart Surg Forum 2010;13(5):E275-9.

Индекс‎: PubMed 20961825

DOI‎: 10.1532/HSF98.20101027

https://www.ncbi.nlm.nih.gov/pubmed/20961825 (отвара нови прозор)

Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes. (отвара нови прозор)

Masud F, Bostan F, Chi E, Pass SE, Samir H, Stuebing K, Liebl MG.

Извор‎: J Cardiothorac Vasc Anesth 2009;23(1):28-33.

Индекс‎: PubMed 18948033

DOI‎: 10.1053/j.jvca.2008.08.003

https://www.ncbi.nlm.nih.gov/pubmed/18948033 (отвара нови прозор)

Recombinant activated factor VII significantly reduces transfusion requirements in cardiothoracic surgery. (отвара нови прозор)

Omar HR, Enten G, Karlnoski R, Ching YH, Mangar D, Camporesi EM.

Извор‎: Drugs R D 2015;15(2):187-94.

Индекс‎: PubMed 25862216

DOI‎: 10.1007/s40268-015-0093-9

https://www.ncbi.nlm.nih.gov/pubmed/25862216 (отвара нови прозор)

Hemostatic management of severe thrombocytopenia in a patient undergoing pulmonic valve replacement. (отвара нови прозор)

Tanaka KA, Li P, McHugh SM, Subramaniam K.

Извор‎: A A Case Rep 2015;5(1):3-5.

Индекс‎: PubMed 26125690

DOI‎: 10.1213/XAA.0000000000000166

https://www.ncbi.nlm.nih.gov/pubmed/26125690 (отвара нови прозор)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (отвара нови прозор)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Извор‎: Anesthesiology 2003;98(6):1513-5.

Индекс‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (отвара нови прозор)

Recombinant activated factor VII in cardiac surgery: a systematic review. (отвара нови прозор)

Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, Darzi A, Athanasiou T.

Извор‎: Ann Thorac Surg 2007;83(2):707-14.

Индекс‎: PubMed 17258029

DOI‎: 10.1016/j.athoracsur.2006.10.033

https://www.ncbi.nlm.nih.gov/pubmed/17258029 (отвара нови прозор)

Reduced use of allogeneic platelets through high-yield perioperative autologous plateletpheresis and reinfusion. (отвара нови прозор)

Alberts M, Bandarenko N, Gaca J, Lockhart E, Milano C, Alexander S, Linder D, Lombard FW, Welsby IJ.

Извор‎: Transfusion 2014;54(5):1348-57.

Индекс‎: PubMed 24898456

DOI‎: 10.1111/trf.12463

https://www.ncbi.nlm.nih.gov/pubmed/24898456 (отвара нови прозор)

Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. (отвара нови прозор)

Arnékian V, Camous J, Fattal S, Rézaiguia-Delclaux S, Nottin R, Stéphan F.

Извор‎: Interact Cardiovasc Thorac Surg 2012;15(3):382-9.

Индекс‎: PubMed 22623627

DOI‎: 10.1093/icvts/ivs224

https://www.ncbi.nlm.nih.gov/pubmed/22623627 (отвара нови прозор)

Reducing blood transfusion in aortic surgery: a novel approach. (отвара нови прозор)

Birla R, Nawaytou O, Shaw M, Jackson A, Mills K, Kuduvalli M, Field M, Agarwal S

Извор‎: Ann Thorac Surg 2019;108(5):1369-75.

Индекс‎: PubMed 31255616

DOI‎: 10.1016/j.athoracsur.2019.04.127

https://www.ncbi.nlm.nih.gov/pubmed/31255616 (отвара нови прозор)

Prophylactic use of factor IX concentrate in a Jehovah's Witness patient. (отвара нови прозор)

Bolliger D, Sreeram G, Duncan A, Molinaro RJ, Szlam F, Chen EP, Tanaka KA.

Извор‎: Ann Thorac Surg 2009;88(5):1666-8.

Индекс‎: PubMed 19853132

DOI‎: 10.1016/j.athoracsur.2009.03.095

https://www.ncbi.nlm.nih.gov/pubmed/19853132 (отвара нови прозор)

Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. (отвара нови прозор)

Cappabianca G, Mariscalco G, Biancari F, Maselli D, Papesso F, Cottini M, Crosta S, Banescu S, Ahmed AB, Beghi C.

Извор‎: Crit Care 2016;20:5.

Индекс‎: PubMed 26738468

DOI‎: 10.1186/s13054-015-1172-6

https://www.ncbi.nlm.nih.gov/pubmed/26738468 (отвара нови прозор)

Bloodless orthotopic heart transplantation in a Jehovah's Witness. (отвара нови прозор)

Dallas T, Welsby I, Bottiger B, Milano C, Daneshmand M, Guinn N.

Извор‎: A A Case Rep 2015;4(10):140-2.

Индекс‎: PubMed 25974419

DOI‎: 10.1213/XAA.0000000000000067

https://www.ncbi.nlm.nih.gov/pubmed/25974419 (отвара нови прозор)

State of the art - how I manage coagulopathy in cardiac surgery patients. (отвара нови прозор)

Davidson S.

Извор‎: Br J Haematol 2014;164(6):779-89.

Индекс‎: PubMed 24450971

DOI‎: 10.1111/bjh.12746

https://www.ncbi.nlm.nih.gov/pubmed/24450971 (отвара нови прозор)

First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. (отвара нови прозор)

Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E, Thielmann M, Jakob H, Peters J.

Извор‎: Anesthesiology 2011;115(6):1179-91.

Индекс‎: PubMed 21970887

DOI‎: 10.1097/ALN.0b013e31823497dd

https://www.ncbi.nlm.nih.gov/pubmed/21970887 (отвара нови прозор)

Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. (отвара нови прозор)

Karkouti K, Bartoszko J, Grewal D, Bingley C, Armali C, Carroll J, Hucke HP, Kron A, McCluskey SA, Rao V, Callum J

Извор‎: JAMA Netw Open 2021;4(4):e213936.

Индекс‎: PubMed 33792729

DOI‎: 10.1001/jamanetworkopen.2021.3936

https://www.ncbi.nlm.nih.gov/pubmed/33792729 (отвара нови прозор)

Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. (отвара нови прозор)

Karlsson M, Ternström L, Hyllner M, Baghaei F, Flinck A, Skrtic S, Jeppsson A.

Извор‎: Thromb Haemost 2009;102(1):137-44.

Индекс‎: PubMed 19572078

DOI‎: 10.1160/TH08-09-0587

https://www.ncbi.nlm.nih.gov/pubmed/19572078 (отвара нови прозор)

Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo-controlled trial. (отвара нови прозор)

Rahe-Meyer N, Hanke A, Schmidt DS, Hagl C, Pichlmaier M.

Извор‎: J Thorac Cardiovasc Surg 2013;145(3 Suppl):S178-85.

Индекс‎: PubMed 23410777

DOI‎: 10.1016/j.jtcvs.2012.12.083

https://www.ncbi.nlm.nih.gov/pubmed/23410777 (отвара нови прозор)

Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. (отвара нови прозор)

Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sørensen B, Hagl C, Pichlmaier M.

Извор‎: Anesthesiology 2013;118(1):40-50.

Индекс‎: PubMed 23249928

DOI‎: 10.1097/ALN.0b013e3182715d4d

https://www.ncbi.nlm.nih.gov/pubmed/23249928 (отвара нови прозор)

Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. (отвара нови прозор)

Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A; Surgical Clinical Outcome REsearch (SCORE) Group.

Извор‎: J Am Heart Assoc 2015;4(6):e002066.

Индекс‎: PubMed 26037084

DOI‎: 10.1161/JAHA.115.002066

https://www.ncbi.nlm.nih.gov/pubmed/26037084 (отвара нови прозор)

Fibrinogen supplementation after cardiac surgery: insights from the zero-plasma trial (ZEPLAST). (отвара нови прозор)

Ranucci M, Baryshnikova E.

Извор‎: Br J Anaesth 2016;116(5):618-23.

Индекс‎: PubMed 26893405

DOI‎: 10.1093/bja/aev539

https://www.ncbi.nlm.nih.gov/pubmed/26893405 (отвара нови прозор)

Bleeding in a Jehovah's Witness patient undergoing a redo aortic valve replacement controlled with cryoprecipitate and a prothrombin complex concentrate. (отвара нови прозор)

Robblee JA, Wilkes PR, Dickie SJ, Rubens FD, Bormanis J.

Извор‎: Can J Anaesth 2012;59(3):299-303.

Индекс‎: PubMed 22161243

DOI‎: 10.1007/s12630-011-9647-7

https://www.ncbi.nlm.nih.gov/pubmed/22161243 (отвара нови прозор)

Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. (отвара нови прозор)

Roman M, Biancari F, Ahmed AB, Agarwal S, Hadjinikolaou L, Al-Sarraf A, Tsang G, Oo AY, Field M, Santini F, Mariscalco G

Извор‎: Ann Thorac Surg 2019;107(4):1275-83.

Индекс‎: PubMed 30458156

DOI‎: 10.1016/j.athoracsur.2018.10.013

https://www.ncbi.nlm.nih.gov/pubmed/30458156 (отвара нови прозор)

Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. (отвара нови прозор)

Sniecinski RM, Chen EP, Levy JH, Szlam F, Tanaka KA.

Извор‎: Anesth Analg 2007;104(4):763-5.

Индекс‎: PubMed 17377078

DOI‎: 10.1213/01.ane.0000250913.45299.f3

https://www.ncbi.nlm.nih.gov/pubmed/17377078 (отвара нови прозор)

Haemostatic therapy in coronary artery bypass graft patients with decreased platelet function: comparison of fibrinogen concentrate with allogeneic blood products. (отвара нови прозор)

Solomon C, Schöchl H, Hanke A, Calatzis A, Hagl C, Tanaka K, Rahe-Meyer N.

Извор‎: Scand J Clin Lab Invest 2012;72(2):121-8.

Индекс‎: PubMed 22233480

DOI‎: 10.3109/00365513.2011.643818

https://www.ncbi.nlm.nih.gov/pubmed/22233480 (отвара нови прозор)

Effects of desmopressin on platelet function under conditions of hypothermia and acidosis: an in vitro study using multiple electrode aggregometry. (отвара нови прозор)

Hanke AA, Dellweg C, Kienbaum P, Weber CF, Görlinger K, Rahe-Meyer N.

Извор‎: Anaesthesia 2010;65(7):688-91.

Индекс‎: PubMed 20477783

DOI‎: 10.1111/j.1365-2044.2010.06367.x

https://www.ncbi.nlm.nih.gov/pubmed/20477783 (отвара нови прозор)

Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. (отвара нови прозор)

Ranucci M, Nano G, Pazzaglia A, Bianchi P, Casana R, Tealdi DG.

Извор‎: J Cardiothorac Vasc Anesth 2007;21(6):851-4.

Индекс‎: PubMed 18068065

DOI‎: 10.1053/j.jvca.2007.05.009

https://www.ncbi.nlm.nih.gov/pubmed/18068065 (отвара нови прозор)

Desmopressin for reducing postoperative blood loss and transfusion requirements following cardiac surgery in adults. (отвара нови прозор)

Wademan BH, Galvin SD.

Извор‎: Interact Cardiovasc Thorac Surg 2014;18(3):360-70.

Индекс‎: PubMed 24263581

DOI‎: 10.1093/icvts/ivt491

https://www.ncbi.nlm.nih.gov/pubmed/24263581 (отвара нови прозор)

A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery. (отвара нови прозор)

Weber CF, Dietrich W, Spannagl M, Hofstetter C, Jámbor C.

Извор‎: Anesth Analg 2010;110(3):702-7.

Индекс‎: PubMed 20042444

DOI‎: 10.1213/ANE.0b013e3181c92a5c

https://www.ncbi.nlm.nih.gov/pubmed/20042444 (отвара нови прозор)

A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. (отвара нови прозор)

Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH.

Извор‎: Ann Surg 2010;251(2):217-28.

Индекс‎: PubMed 20010084

DOI‎: 10.1097/SLA.0b013e3181c3bcca

https://www.ncbi.nlm.nih.gov/pubmed/20010084 (отвара нови прозор)

A review of topical hemostatic agents for use in cardiac surgery. (отвара нови прозор)

Barnard J, Millner R.

Извор‎: Ann Thorac Surg 2009;88(4):1377-83.

Индекс‎: PubMed 19766855

DOI‎: 10.1016/j.athoracsur.2009.02.092

https://www.ncbi.nlm.nih.gov/pubmed/19766855 (отвара нови прозор)

Armentarium of topical hemostatic products in cardiovascular surgery: an update. (отвара нови прозор)

Forcillo J, Perrault LP.

Извор‎: Transfus Apher Sci 2014;50(1):26-31.

Индекс‎: PubMed 24412443

DOI‎: 10.1016/j.transci.2013.12.009

https://www.ncbi.nlm.nih.gov/pubmed/24412443 (отвара нови прозор)

A novel reverse thermosensitive polymer to achieve temporary atraumatic vessel occlusion in infra-popliteal bypasses. (отвара нови прозор)

Mani K, Campbell A, Fitzpatrick J, Modarai B, Carrell T, Rashid H, Zayed H.

Извор‎: Eur J Vasc Endovasc Surg 2013;45(1):51-6.

Индекс‎: PubMed 23134676

DOI‎: 10.1016/j.ejvs.2012.10.008

https://www.ncbi.nlm.nih.gov/pubmed/23134676 (отвара нови прозор)

Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. (отвара нови прозор)

Menkis AH, Martin J, Cheng DC, Fitzgerald DC, Freedman JJ, Gao C, Koster A, Mackenzie GS, Murphy GJ, Spiess B, Ad N.

Извор‎: Innovations (Phila) 2012;7(4):229-41.

Индекс‎: PubMed 23123988

DOI‎: 10.1097/IMI.0b013e3182747699

https://www.ncbi.nlm.nih.gov/pubmed/23123988 (отвара нови прозор)

Control of troublesome bleeding during repair of acute type A dissection with use of modified rapid deployment hemostat (MRDH). (отвара нови прозор)

Salerno TA, Gaughan C, Suarez M, Panos AL.

Извор‎: J Card Surg 2009;24(6):722-4.

Индекс‎: PubMed 20078720

DOI‎: 10.1111/j.1540-8191.2009.00915.x

https://www.ncbi.nlm.nih.gov/pubmed/20078720 (отвара нови прозор)

Topical haemostatic agents. (отвара нови прозор)

Seyednejad H, Imani M, Jamieson T, Seifalian AM.

Извор‎: Br J Surg 2008;95(10):1197-225.

Индекс‎: PubMed 18763249

DOI‎: 10.1002/bjs.6357

https://www.ncbi.nlm.nih.gov/pubmed/18763249 (отвара нови прозор)

An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit. (отвара нови прозор)

Anderson L, Quasim I, Soutar R, Steven M, Macfie A, Korte W.

Извор‎: Transfus Med 2006;16(1):31-9.

Индекс‎: PubMed 16480437

DOI‎: 10.1111/j.1365-3148.2006.00645.x

https://www.ncbi.nlm.nih.gov/pubmed/16480437 (отвара нови прозор)

First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. (отвара нови прозор)

Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E, Thielmann M, Jakob H, Peters J.

Извор‎: Anesthesiology 2011;115(6):1179-91.

Индекс‎: PubMed 21970887

DOI‎: 10.1097/ALN.0b013e31823497dd

https://www.ncbi.nlm.nih.gov/pubmed/21970887 (отвара нови прозор)

Management of hemorrhage in cardiothoracic surgery. (отвара нови прозор)

Görlinger K, Shore-Lesserson L, Dirkmann D, Hanke AA, Rahe-Meyer N, Tanaka KA.

Извор‎: J Cardiothorac Vasc Anesth 2013;27(4 Suppl):S20-34.

Индекс‎: PubMed 23910533

DOI‎: 10.1053/j.jvca.2013.05.014

https://www.ncbi.nlm.nih.gov/pubmed/23910533 (отвара нови прозор)

Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. (отвара нови прозор)

Weber CF, Görlinger K, Meininger D, Herrmann E, Bingold T, Moritz A, Cohn LH, Zacharowski K.

Извор‎: Anesthesiology 2012;117(3):531-47.

Индекс‎: PubMed 22914710

DOI‎: 10.1097/ALN.0b013e318264c644

https://www.ncbi.nlm.nih.gov/pubmed/22914710 (отвара нови прозор)